TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival
Animals
Cells, Cultured
Flow Cytometry
Forkhead Transcription Factors
/ genetics
Interferon-gamma
/ pharmacology
Interleukin-1beta
/ pharmacology
Lentivirus
/ genetics
Lung
/ cytology
Male
Mesenchymal Stem Cells
/ cytology
Nitrogen Oxides
/ metabolism
Rats
Reverse Transcriptase Polymerase Chain Reaction
T-Lymphocytes, Regulatory
/ drug effects
Tumor Necrosis Factor-alpha
/ pharmacology
MSC priming
immune
immunomodulation
transplantation
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
21
5
2019
medline:
2
6
2020
entrez:
21
5
2019
Statut:
ppublish
Résumé
Mesenchymal stromal cells (MSCs) have shown promise as a therapy for immune-mediated disorders, including transplant rejection. Our group previously demonstrated the efficacy of pretransplant, systemic administration of allogeneic but not syngeneic MSCs in a rat cornea transplant model. The aim of this study was to enhance the immunomodulatory capacity of syngeneic MSCs.
Identifiants
pubmed: 31108041
doi: 10.1096/fj.201900047R
doi:
Substances chimiques
Forkhead Transcription Factors
0
Foxp3 protein, rat
0
Interleukin-1beta
0
Nitrogen Oxides
0
Tumor Necrosis Factor-alpha
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM